Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dual-target CAR-T cells (Beijing Biotech)
- Development stage
- Phase 2
- Lead developer
- Immunochina Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous dual-target CAR-T cell therapy is an experimental cellular immunotherapy developed by Beijing Biotech (Beijing Immunochina) for the treatment of advanced solid tumors. This therapy utilizes a biomarker-guided approach where a patient's tumor is screened for specific antigens, and the most appropriate dual-target CAR-T construct is selected from a predefined library. By targeting two tumor-associated antigens simultaneously, the therapy aims to enhance tumor specificity, overcome antigen heterogeneity, and mitigate the risk of antigen escape, which are common challenges in treating solid malignancies with single-target CAR-T cells. The treatment involves lymphodepletion with fludarabine and cyclophosphamide followed by a single infusion of the engineered T cells.
- Other names
- autologous dual-target CAR-T cells-Beijing Biotech-solid tumorBiomarker-Guided Dual-Target CAR-T
Beyond the preview
Go deeper on autologous dual-target CAR-T cells (Beijing Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dual-target CAR-T cells (Beijing Biotech).